This is a highlights summary of an oral session given at the ACR Convergence 2020 and presented by:

Maya Buch, MD, PhD
University of Manchester
Manchester, United Kingdom

The presenting authors of the original session had no part in the creation of this conference highlights summary.

In addition, an expert commentary on the topic has been provided by:

Jonathan Kay, MD
University of Massachusetts Medical School, Worcester, MA, USA

The content is produced by Infomedica, an approved ACR education partner. The summary text was drafted by Marie Farrow, and reviewed by Alessia Alunno, MD, PhD, an independent external expert, and approved by Atul Deodhar, MD, MRCP, the scientific editor of the program.
This activity is included in the ACR's Education Partner program. Independent reporting and the viewpoints expressed are those of Infomedica and its affiliates and do not represent the ACR.

Jonathan Kay, MD
University of Massachusetts Medical School, Worcester, MA, USA

Jonathan Kay, MD, is Professor of Medicine and Population and Quantitative Health Sciences and holds the Timothy S. and Elaine L. Peterson Chair in Rheumatology at the University of Massachusetts Medical School in Worcester, where he directs clinical research in the Division of Rheumatology. His clinical appointment is as a Physician at UMass Memorial Medical Center, also in Worcester. He received his medical degree from the University of California School of Medicine in San Francisco, California. He then completed an internship and residency at the Hospital of the University of Pennsylvania in Philadelphia and fellowships in rheumatology and immunology at the Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts.

Dr. Kay is a Fellow of the American College of Rheumatology and of the American College of Physicians. In 2018, he received the Distinguished Service Award from the American College of Rheumatology and he was awarded honorary membership in EULAR. He is an ad hoc reviewer for many journals, and a member of the editorial boards of Best Practice and Research Clinical Rheumatology and RMD Open.

Dr. Kay’s clinical interests span the spectrum of rheumatic diseases, with special interest in rheumatoid arthritis, spondyloarthropathies, and other forms of inflammatory arthritis. He was a member of the group that developed the 2010 ACR/EULAR Diagnostic and Classification Criteria for Rheumatoid Arthritis. He chaired the Rheumatology Working Group and was a member of the Internal Medicine and Musculoskeletal Topic Advisory Groups for the World Health Organization in its Revision of the International Classification of Diseases (ICD)-11.

Over the past three decades, his clinical research has focused on nephrogenic systemic fibrosis (formerly known as nephrogenic fibrosing dermopathy), ß2-microglobulin amyloidosis, and other rheumatologic problems of patients with chronic kidney disease. He has been a principal investigator on over 60 clinical trials of novel therapies for rheumatoid arthritis, axial spondyloarthritis, gout, and osteoarthritis. Over the past decade, he has been involved in the development of biosimilars to treat rheumatic diseases. Dr. Kay lectures internationally and is the author of more than 240 publications and book chapters.

1. Haselmayer P, Camps M, Liu-Bujalski L, et al. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models. J Immunol 2019;202:2888–906.

2. Norman P. Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Expert Opin Invest Drugs 2016;25:891–9.